Roche infectious news
Roche discontinued development of an undisclosed number of preclinical compounds to treat HIV, due to an inability to “deliver substantial improvement over existing medicines.” The compounds target the CC chemokine receptor ( CCR5) entry pathway and reverse transcriptase enzymes. Roche will assess a license or sale of the compounds. The decision does not affect Roche’s marketed HIV drugs, including Fuzeon enfuvirtide, Invirase saquinavir, and Viracept nelfinavir. Fuzeon, a viral fusion inhibitor peptide analog based on HIV gp41, is licensed from Trimeris Inc. (NASDAQ:TRMS, Morrisville, N.C.). Invirase and Viracept are HIV protease inhibitors. Viracept is marketed in the U.S., Canada and Japan by Pfizer Inc. (NYSE:PFE, New York, N.Y.). ...